Chinese PLA General Hospital (CAR-T cell technology) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Chinese PLA General Hospital (CAR-T cell technology) General Information
Description
Biologic cancer therapy asset. The asset consists of Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and human epidermal growth factor receptor's immuno-oncology patents, and phase I/II clinical data of the therapies and manufacturing knowledge. The CAR-T cell therapy involves engineering cancer patients' own immune cells to recognize and attack their tumors.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Primary Office
- 28 fuxing road
- Beijing
- China
Chinese PLA General Hospital (CAR-T cell technology) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Chinese PLA General Hospital (CAR-T cell technology) Patents
Chinese PLA General Hospital (CAR-T cell technology) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3913576-A1 | Deep-learning-based method for predicting morphological change of liver tumor after ablation | Pending | 04-Nov-2019 | 000000000 | |
| US-20200345500-A1 | Tissue engineering meniscal composite scaffold and preparation method thereof | Pending | 30-Aug-2018 | 000000000 | |
| JP-2013530939-A | Urea compounds and their use to inhibit apoptosis | Granted | 14-May-2010 | 0000000000 | 0 |
| JP-5752239-B2 | Urea compounds and their use to inhibit apoptosis | Active | 14-May-2010 | 0000000000 | |
| EP-2570403-B1 | Urea compounds and use thereof for inhibiting apoptosis | Active | 14-May-2010 | C07C275/28 |
Chinese PLA General Hospital (CAR-T cell technology) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|